Publications by authors named "Jeremy Lapiere"

Claim this Profile
T
The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma.
Nicolas Albin, Adrien Monard, Jérémy Lapiere

Cancer Chemother Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis